- No public price.
- Not disclosed
- Not disclosed
- —
- 1997
- US
Radiology
TeraRecon
by ConcertAI · founded 1997 · US
Advanced CT and MR visualization with cardiac, aorta and neuro AI, plus a vendor-agnostic platform to run third-party AI.
On this page
42/100
Editorial rating 3.0 / 5
- Regulatory & Compliance18/28
FDA cleared (7 K-numbers on record)
- Clinical Integration0/6.6
No EHR integrations listed
- Evidence Strength0/26
No peer-reviewed coverage
- Vendor & Market14.4/18
Mid-tier funding and adoption
- Sentiment & Transparency2.5/5
Pricing on request, no public amounts
▸ Show all 11 dimensions▾ Hide dimension detail
- FDA clearance18/18
FDA cleared (7 K-numbers on record)
- HIPAA / SOC2 / BAA0/10
No public HIPAA/SOC2/BAA attestation
- EHR integrations (count)0/4
No EHR integrations listed
- Top-3 EHR coverage (Epic / Oracle / Athena)0/2
None of the top-3 EHRs covered
- Peer-reviewed papers0/18
No peer-reviewed coverage
- RCT / meta-analysis / systematic review0/8
No RCT, meta-analysis, or systematic review
- Funding & adoption signal8/12
Mid-tier funding and adoption
- Years in market6/6
Founded 1997 (29 years)
- Pricing transparency3/5
Pricing on request, no public amounts
Advanced CT and MR visualization with cardiac, aorta and neuro AI, plus a vendor-agnostic platform to run third-party AI.
No public price.
Evidence record
510(k)K250288 (opens in new tab)October 23, 2025
TeraRecon Cardiovascular.Calcification.CT
510(k)K243158 (opens in new tab)January 23, 2025
TeraRecon Aorta.CT (1.1.0)
510(k)K241312 (opens in new tab)November 5, 2024
TeraRecon Cardiac.Chambers.MR (1.0.0)
510(k)K220349 (opens in new tab)August 12, 2022
TeraRecon Neuro
510(k)K200750 (opens in new tab)November 6, 2020
Neuro.AI Algorithm
Show 2 more
510(k)K191585 (opens in new tab)July 12, 2019
iNtuition-Structural Heart Module
510(k)K180916 (opens in new tab)September 24, 2018
iNtuition-T1 Mapping and T2/T2* Mapping
- Score computed November 2, 2026, method 1.2.0
- Review written November 2, 2026
MedAI Verdict, TeraRecon record, https://medaiverdict.com/tools/terarecon, version November 2, 2026
Bottom line
TeraRecon is mostly advanced visualization and post-processing for CT and MR, with an AI Framework that hosts other vendors' algorithms and a few of its own cleared algorithms for the aorta, cardiac MR, coronary calcium and neuro perfusion. TeraRecon AV is registered as Intuition in global markets. SymphonyAI acquired the company in 2020 per its About page, and releases since 2024 are titled "ConcertAI's TeraRecon." Imaging departments that want a viewer plus one host for several AI vendors fit. Standalone triage or notification AI is not in its record, since none of the decisions in openFDA's applicant search is a triage or notification device.
What does TeraRecon sell?
The home page lists TeraRecon AV, Intuition, TR Neuro, DETECT and the AI Framework, and describes "advanced visualization at scale" with clinical AI for high-value CT and MRI studies. Intuition is a cloud-based SaaS platform with cardiac MR workflows: a CMR viewer, 2D flow, semi-quantitative perfusion and strain. A November 20, 2025 release announced new structural heart and SaaS capabilities for TeraRecon AV, including TMVR and left atrial appendage reports. Intuition passes results to reporting systems over DICOM and HL7.
The AI Framework hosts clinical and non-clinical algorithms from a library of partners, allows several per study, compares with priors and requires physician review before results are committed. DETECT runs imaging biomarkers during review in three modules: Plaque Analysis for cardiac CT, Hepatic Analysis for liver density and Spine Analysis for vertebral compression fractures and bone density. The vendor says it supports FDA-cleared biomarkers and claims more than 2,000 hospitals.
Which algorithms has TeraRecon cleared itself?
openFDA lists decisions from K974307 (RTR-2000 and RTR-4000, February 13, 1998) to K250288 (Cardiovascular.Calcification.CT, October 23, 2025). The recent algorithmic ones are Cardiac.Chambers.MR in 2024, Aorta.CT in January 2025 and Cardiovascular.Calcification.CT in October 2025, the last limited to GE or Siemens CT on the regulatory page. Neuro.AI in 2020 and TeraRecon Neuro in 2022 cover CT and MR perfusion analysis. Two others quantify or measure: T1 and T2/T2* mapping on MR in 2018 and a structural heart module in 2019. Older entries are workstation and viewing software, including INTUITION in 2013 for receiving, storing, post-processing and displaying images from CT, MR, PET and other modalities.
How do SymphonyAI and ConcertAI figure in the ownership?
The About page says SymphonyAI Group acquired the company in 2020 as an independent portfolio company, and its timeline lists a 2021 item, "ConcertAI Announces Integration of TeraRecon." Newsroom releases since 2024 carry the title "ConcertAI's TeraRecon."
Do published studies evaluate its AI?
The PubMed record around TeraRecon is mostly clinical work that used a TeraRecon (Aquarius) workstation for segmentation or volumetry, such as a 2025 Pediatric Cardiology paper on CT volumetry reproducibility in congenital heart disease (PMID 39217235). No evaluation of a TeraRecon AI feature was found in PubMed.
How is it priced?
No price is public.
The verdict
An imaging department that values visualization first and a hosting layer for third-party algorithms second is the buyer. The cleared record for TeraRecon's own algorithms has decisions but no accuracy evaluation in PubMed to go with them.
Editorial review last generated November 2, 2026. Synthesized from clinician sentiment, peer-reviewed coverage, and our editorial silo picks. Refined by hand where vendor facts change.
What it costs
All tiers are custom-quoted. The vendor does not publish per-provider list pricing.
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | Not stated | Not stated | No public price. |
Source: vendor pricing page. Last checked November 2, 2026.
What deploys cleanly
Carries FDA 510(k) per vendor documentation. Independent attestation review is the buyer's responsibility before clinical deployment.
Who builds it
TeraRecon (ConcertAI) was founded in 1997 in US, putting it 29 years into market.
Other radiology
See the full radiology ranking
Siemens Healthineers AI-Rad Companion
by Siemens Healthineers
AI-Rad Companion: Chest CT, Chest X-ray, Brain MR, Prostate MR and Organs RT (radiotherapy contouring) modules, delivered through teamplay.
No public price on the vendor page.|FDA 510(k) (multiple) / CE Mark (MDD/MDR. MDR status not verified)
GE HealthCare AI Suite
by GE HealthCare
Portfolio of separately cleared AI-enabled GE HealthCare devices and software, including AIR Recon DL, Sonic DL, Critical Care Suite, Caption AI and icobrain.
No public price. Products are sold with scanners or as scanner options, on enterprise quotes.|FDA 510(k) (multiple)
Aidoc
by Aidoc
Clinical AI platform (aiOS) with FDA-cleared triage, notification and quantification algorithms for radiology and neurovascular care.
Private offer only. No trial is stated.|FDA 510(k) (multiple) / EU MDR 2017/745
Viz.ai
by Viz.ai
Care coordination platform with FDA-cleared imaging AI for stroke, vascular and cardiac conditions.
No public price. Sold to health systems after a demo request.|FDA 510(k) (multiple) / FDA De Novo (ContaCT, Viz HCM)